RxDoctor Payments Data

Terry Roach, DO

Family Medicine · Hurst, TXNPI 1831162585

Payments from drug & device makers

$12,020in general payments, 2019–2025

Across 541 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$1K
  • Novo Nordisk$907
  • Boehringer Ingelheim$755
  • Lilly USA, LLC$536
  • Pfizer$533
  • plus $4K from 41 others

What the payments were for

  • Speaking & faculty fees$3,36028%
  • Food & beverage$8,62372%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,020 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$51,284
Medicare patients
171
Services billed
614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$94,788
OzempicSemaglutide68$85,829
FarxigaDapagliflozin Propanediol114$85,629
EliquisApixaban65$68,684
RybelsusSemaglutide27$30,281
MounjaroTirzepatide17$25,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$22,525
Synjardy XrEmpagliflozin/Metformin Hcl22$17,726
TrulicityDulaglutide14$15,015
LinzessLinaclotide20$14,622
MyrbetriqMirabegron14$14,002
Tresiba Flextouch U-200Insulin Degludec19$13,537
VascepaIcosapent Ethyl23$13,080
Breo ElliptaFluticasone/Vilanterol13$8,442
Spiriva RespimatTiotropium Bromide11$5,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$755$118,335123 claims
Novo NordiskOzempic, Rybelsus$907$116,11095 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort$1,314$93,597137 claims
PfizerEliquis$533$68,68465 claims
Lilly USA, LLCMounjaro, Trulicity$536$40,30731 claims
GSKTrelegy Ellipta, Breo Ellipta$353$30,96638 claims
AbbVieLinzess, Synthroid$4,158$16,52940 claims
Astellas Pharma US IncMyrbetriq$123$14,00214 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$70$1,478234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Hurst

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →